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Abstract. The Src kinase family (SKF) includes non-receptor 
tyrosine kinases that interact with many cellular cytosolic, 
nuclear and membrane proteins, and is involved in the 
progression of cellular transformation and oncogenic activity. 
However, there is little to no evidence on the effect of SKF 
or its inhibitors on melanogenesis. Therefore, the present 
study investigated whether C-terminal Src kinase inhibi-
tion can induce melanogenesis and examined the associated 
signaling pathways and mRNA expression of melanogenic 
proteins. First, whether stimulators of melanogenesis, such 
as ultraviolet B and α-melanocyte-stimulating hormone, can 
dephosphorylate Src protein was evaluated, and the results 
revealed that SU6656 and PP2 inhibited the phosphorylation 
of Src in G361 cells. Src inhibition by these chemical inhibi-
tors induced melanogenesis in G361 cells and upregulated the 
mRNA expression levels of melanogenesis-associated genes 
encoding microphthalmia-associated transcription factor, 
tyrosinase-related protein 1 (TRP1), TRP2, and tyrosinase. 
In addition, Src inhibition by small interfering RNA induced 
melanogenesis and upregulated the mRNA expression levels of 
melanogenesis-associated genes. As the p38 mitogen-activated 
protein kinase (MAPK) and cyclic adenosine monophosphate 
response element binding (CREB) pathways serve key roles 
in melanogenesis, the present study further examined whether 
Src mediates melanogenesis via these pathways. As expected, 
Src inhibition via SU6656 or PP2 administration induced the 
phosphorylation of p38 or CREB, as determined by western 
blotting analysis, and increased the levels of phosphorylated 
p38 or CREB, as determined by immunofluorescence staining. 
In addition, the induced pigmentation and melanin content of 
G361 cells by Src inhibitors was significantly inhibited by 
p38 or CREB inhibitors. Taken together, these data indicate 
that Src is associated with melanogenesis, and Src inhibition 
induces melanogenesis via the MAPK and CREB pathways 
in G361 cells.
Introduction
Melanin is an important factor in determining the color 
of the human skin, hair and eyes (1,2). It is produced in the 
melanosome through a complex process known as melano-
genesis (3-5). In addition, melanin serves an important role in 
photoprotection from ultraviolet (UV) radiation and external 
stress (1,3). Growth factors, cytokines, hormones and other 
receptor ligands exert their function by interacting with their 
receptors on the cell surface, generating a signaling cascade 
and leading to distinct patterns of protein phosphorylation. 
Melanocytes express several distinct receptor tyrosine kinases 
(RTKs) that bind bone morphogenic protein (BMP), hepatocyte 
growth factor (HGF) and c-Kit ligand. For example, BMP-2 
stimulates tyrosinase gene expression and melanogenesis in 
differentiated melanocytes, and BMP signaling controls hair 
pigmentation via cross-talk with the melanocortin receptor-1 
pathway (6). The activation of Met in response to HGF acts as 
a mitogen for melanocytes and synergistically contributes to 
malignant progression with the aberrant expression of basic 
fibroblast growth factor in malignant melanocytes (7). Normal 
human melanocytes and melanoma cells express the c-Kit 
gene and stem cell factor (SCF), a ligand of the c-Kit receptor 
that upregulates the expression of melanogenic proteins (8). 
In addition, SCF/c-Kit signaling is required for cyclic regen-
eration of the hair pigmentation unit (9). Phosphorylation 
of these RTKs subsequently activates a series of kinases 
known as mitogen-activated protein kinases (MAPKs) 
or other intracellular signaling molecules such as cyclic 
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adenosine monophosphate (10). Then, following the phos-
phorylation of proteins such as microphthalmia-associated 
transcription factor (MITF), the transcription of genes that 
participate in melanocyte proliferation and melanogenesis is 
activated (11).
The Src kinase family (SKF) is a family of non-receptor 
tyrosine kinases that is composed of nine members including 
Src, Yes and Fyn. SKF interacts with many cellular cytosolic, 
nuclear and membrane proteins, modifying these proteins 
by phosphorylating tyrosine residues and contributing to 
the progression of cellular transformation and oncogenic 
activity (12). Of these, C-terminal Src kinase (c-Src) is 
encoded by the SRC gene in humans; it phosphorylates 
specific tyrosine residues in other proteins. c‑Src can be acti-
vated by many transmembrane proteins including RTKs, such 
as platelet-derived growth factor receptor, epidermal growth 
factor receptor, and c-Kit. Therefore, c-Src is closely associated 
with the RTK pathways (13). As RTKs serve a critical role in 
the development and progression of many types of cancer (12), 
an elevated activity level of c-Src tyrosine kinase is associ-
ated with the progression of different types of cancers, such 
as pancreatic and breast cancers (14). Therefore, diverse Src 
inhibitors have been developed to prevent cancer progression, 
and drugs against RTKs are widely used in cancer therapy. 
However, there is little to no evidence on the effects of SKF 
or its inhibitors on melanocytes. Therefore, the present study 
investigated the effect of a c-Src inhibitor on melanocytes and 
its associated signaling pathways.
Materials and methods
Cell cultures and chemical treatment. Human G361 melanoma 
cells (cat. no. ATCC® CRL-1424™; American Type Culture 
Collection, Manassas, VA, USA) were cultured in low glucose 
Dulbecco's modified Eagle's medium with 10% fetal bovine 
serum (FBS; Gibco; Thermo Fisher Scientific, Inc., Waltham, 
MA, USA) and 1% penicillin/streptomycin (Gibco; Thermo 
Fisher Scientific, Inc.). G361 cells were maintained at 37˚C 
in a humidified 5% CO2 incubator. α-Melanocyte-stimulating 
hormone (α-MSH; Sigma-Aldrich; Merck KGaA, Darmstadt, 
Germany), SU6656 (cat. no. S7774; Selleck Chemicals, 
Houston, TX, USA), PP2 (cat. no. S7008; Selleck Chemicals), 
H-89 [protein kinase A (PKA) inhibitor; cat. no. B1427; 
Sigma-Aldrich; Merck KGaA], SB203580 (p38 inhibitor; 
cat. no. S8307; Sigma-Aldrich; Merck KGaA) dasatinib (cat. 
no. CDS023389; Sigma-Aldrich; Merck KGaA) and nilotinib 
(cat. no. CDS023093; Sigma-Aldrich; Merck KGaA) were 
utilized in the present study. For these chemical treatments 
in all of the experiments, 1x105 cells were seeded in a 6-well 
plate for 2 days at 37˚C with normal medium including 10% 
FBS and 1% penicillin/streptomycin and were changed with 
normal media, which included the aforementioned chemicals. 
All cells, except those used for western blotting and siRNA 
transfection experiments, were incubated for 9 days following 
chemical treatments at 37˚C. For western blotting, α-MSH 
treated cells were harvested at 0, 5, 15 and 30 min. SU6656 or 
PP2 treated cells were harvested at 0, 5, 15, 30, 60 or 120 min. 
For melanin content measurement, cells were treated with 
α-MSH (1 µM), dasatinib and nilotinib (both at 0.1 M) for 0, 
3, 6, and 9 days, and then cells were harvested. Cells were 
treated with SU6656 and PP2 at different doses (1, 10, 100 and 
1000 nM) and harvested 9 days later.
Drug solution preparation. All chemical concentrations 
employed in the present study were presented as stock/working 
concentrations as follows; α-MSH was used at 200 µM/1 µM, 
and SU6656 and PP2 were used as 0.2 µM/1 nM, 2 µM/10 nM, 
20 µM/100 nM and 200 µM/1,000 nM. The p38 inhibitor 
SB203580 was used at 400 µM/1 µM, and the final concentra-
tion of the p38 inhibitor was 8 mM/20 µM. The PKA inhibitor 
H-89 was used 1 mM/1 µM. Dasatinib and nilotinib were used 
at 10 M/0.1 M.
UV irradiation. A total of 1x105 cells were seeded in plates 
and incubated at 37˚C for 48 h. They were washed with 
phosphate-buffered saline (PBS) and covered with a thin 
layer of PBS prior to UV exposure. The culture plate lid was 
removed and cells were irradiated (UVB: 5 mJ/cm2) in a 
dark box. The UVB irradiation apparatus (BLE-1T158) was 
obtained from Spectronics Corporation (Westbury, NY, USA). 
The incident dose of UVB was measured using a Waldmann 
UV meter (model no. 585100; Herbert Waldmann GmbH & 
Co. KG, Villingen-Schwenningen, Germany). Following UV 
irradiation, PBS was replaced with culture medium at 37˚C. 
The irradiated cells were harvested at 0, 1, 5 and 10 min 
following UV irradiation for western blotting. For melanin 
content measurements, the irradiated cells were also harvested 
at 0, 3, 6 and 9 days.
siRNA transfection. G361 cells were seeded in 60-mm dishes 
at 1x105 cells, and Src siRNA or negative control siRNA were 
transfected using Lipofectamine™ RNAiMAX (Invitrogen; 
Thermo Fisher Scientific, Inc.). The sequences of Src siRNA 
(Bioneer Corporation, Daejeon, Korea; cat #100545; stock 
concentration 100 nM/working concentration 10 or 20 nM) 
was as follows: Sense, GUGUCUUAAUACUGUCCUU(dTdT) 
and antisense, AAGGACAGUAUUAAGACAC(dTdT). The 
sequence of the negative control siRNA is commercially 
unavailable (cat. no. SN-1002; Bioneer Corporation). G361 
cells were harvested following 6 days and mRNA expression 
levels were analyzed via reverse transcription-quantitative 
polymerase chain reaction (RT‑qPCR). Transfection efficiency 
of siRNA was evaluated by qPCR.
Observation of cell pellets and measuring the melanin content. 
To measure the melanin content, cells were seeded in 60-mm 
dishes at 1x105 cells/dish, incubated at 37˚C for 2 days and 
treated at 37˚C with SU6656, PP2, α-MSH, p38 inhibitor, PKA 
inhibitor, Src siRNA (cat. no. 100545), dasatinib and nilotinib 
for 9 days. SU6656 and PP2 were used at 0, 1, 10, 100 and 
1,000 nM, and α-MSH was used at 1 µM. The p38 inhibitor 
(SB203580) was used at 20 µM, PKA inhibitor (H-89) was 
used at 1 µM and Src siRNA was used at 20 nM. Dasatinib 
and nilotinib were used at 0.1 M (data not shown). Cells were 
trypsinized using 0.25% trypsin, harvested by centrifugation 
at 13,000 x g for 1.5 min at 4˚C, photographed and solubi-
lized in boiled 1N NaOH (80˚C) for 2 h; the absorbance 
was then measured at 405 nm, as described previously (15). 
Measurement of melanin contents following UVB irradia-
tion was also conducted in the same manner. The amount of 
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melanin measured in all experiments was normalized to the 
relative value of the control group.
RNA extraction, RT‑qPCR and semi‑quantitative (sq)‑PCR 
analysis. Total RNA was extracted from G361 cells using 
Favor-PrepTM Blood/Cultured cell total RNA purification mini 
kit (Favorgen Biotech Corp., Ping-Tung, Taiwan) and subjected 
to cDNA synthesis using oligodT and the HelixCript™ 
Thermo Reverse Transcription System (NanoHelix Co., Ltd., 
Daejeon, Korea) according to the manufacturer's instructions. 
qPCR amplification of cDNA was performed in a total volume 
of 30 µl under the following thermocycling conditions: Initial 
denaturation at 95˚C for 5 min, followed by 27 cycles of 95˚C 
for 30 sec, 54˚C for 20 sec and 72˚C for 30 sec, and a final exten-
sion at 72˚C for 10 min. For the qPCR reaction, BrightGreen 
qPCR master mix-ROX (Abcam, Cambridge, MA, USA) was 
used and reaction was carried out using Applied biosystems 
qPCR Machine; quantification was conducted using the 2‑∆∆Cq 
method (16). The GAPDH mRNA expression level was used 
for sample standardization. For the quantification of sqPCR 
data, the amplification conditions of all genes were 95˚C 
for 5 min, followed by 40 cycles of 95˚C for 1 min, 55˚C for 
1 min and 72˚C for 1 min, and then a final extension at 72˚C 
for 10 min. Then the samples were loaded onto 1.5% agarose 
gel containing GelRed and electrophoresed. The bands were 
visualized using a UV illuminator. The band intensity of the 
product was calculated using ImageJ (version 1.45; National 
Institutes of Health, Bethesda, MD, USA) (17). For RT-PCR 
the primers used were as follows: MITF forward, 5'-TGC 
CCA GGC ATG AAC ACA C-3', and reverse, 5'-TGG GAA AAA 
TAC ACG CTG TGA G-3'; tyrosinase-related protein 1 (TRP1) 
forward, 5'-TCT CTG GGC TGT ATC TTC TTC C-3' and reverse, 
5'-GTC TGG GCA ACA CAT ACC ACT-3'; TRP2 forward, 
5'-CTT GGG CTG CAA AAT CCT GC-3' and reverse 5'-CAG 
CAC TCC TTG TTC ACT AGG-3'; tyrosinase forward, 5'-TGC 
ACA GAG AGA CGA CTC TTG-3' and reverse 5'-GAG CTG 
ATG GTA TGC TTT GCT AA-3'; GAPDH forward, 5'-GGA 
GCG AGA TCC CTC CAA AAT-3' and reverse, 5'-GGC TGT 
TGT CAT ACT TCT CAT GG-3'.
Western blotting. For western blotting, 1x105 cells were treated 
with SU6656 (1 µM), PP2 (1 µM) or α-MSH (1 µM) for 9 days 
and then lysed with protein extraction solution (PRO-PREP™; 
Intron Biotechnology, Inc., Seongnam, Korea). Protein quan-
tification was performed using a Bicinchoninic Acid (BCA) 
assay kit (Pierce™ BCA Protein Assay kit; Thermo Fisher 
Scientific, Inc.). A total of 70 µg of protein was loaded in a 
12% acrylamide gel and run for 1.5 h; all protein was then 
transferred to a PVDF membrane (Immobilon-P; Merck 
KGaA). The transferred membrane was blocked with 5% 
bovine serum albumin (BSA; Bovogen; Bovogen Biologicals 
Pty Ltd., Keilor East VIC, Australia) blocking buffer for 1 h 
at room temperature, incubated with primary antibodies 
(1:1,000) overnight at 4˚C, washed with PBS several times and 
then incubated with secondary antibodies (1:2,000) at room 
temperature for 1 h. The primary antibodies used were as 
follows: Rabbit phosphorylated (phospho)-Src (cat. no. #6943; 
Cell Signaling Technology, Inc., Danvers, MA, USA), rabbit 
Src (cat. no. 2123; Cell Signaling Technology, Inc.), mouse 
phospho-p38 (cat. no. 9216; Cell Signaling Technology, Inc.), 
rabbit p38 (cat. no. 9212; Cell Signaling Technology, Inc.), 
rabbit phospho-cyclic adenosine monophosphate response 
element binding (CREB; cat. no. 9198; Cell Signaling 
Technology, Inc.), rabbit CREB (cat. no. 9197; Cell Signaling 
Technology, Inc.), mouse β-actin (cat. no. sc-1615; Santa Cruz 
Biotechnology, Inc., Dallas, TX, USA) and mouse α-tubulin 
(cat. no. sc-32293; Santa Cruz Biotechnology, Inc.). The 
secondary antibodies used were as follows: Peroxidase labeled 
anti-mouse immunoglobulin (Ig)-G (cat. no. PI-2000; Vector 
Laboratories, Inc.; Maravai LifeSciences, San Diego, CA, 
USA) and peroxidase labeled anti-rabbit IgG (cat. no. PI-1000; 
Vector Laboratories, Inc.; Maravai LifeSciences). Following 
the addition of Enhanced Chemiluminescence solution 
(Immobilon Western; Merck KGaA), western blotting images 
were obtained using ImageQuant LAS 4000 (GE Healthcare 
Bio-Sciences, Pittsburgh, PA, USA). Band densities were 
quantified using ImageJ software (version 1.45; National 
Institutes of Health, Bethesda, MD, USA). The quantifica-
tion of the phosphorylated protein was calculated as follows: 
(p-protein/internal control)/(total protein/internal control).
Immunofluorescence. For immunofluorescence staining, 
1x105 cells were fixed with 4% paraformaldehyde for 
30 min at room temperature, rinsed in PBS, blocked in 
5% BSA‑containing TBS‑Tx (supplemented with 0.2% 
Triton-X-100) for 1.5 h at room temperature and incubated 
with the primary antibodies overnight at 4˚C. The primary 
antibodies used were anti-mouse phospho (p)-p38 (1:200; 
cat. no. 9216; Cell Signaling Technology, Inc.) and anti-rabbit 
p-CREB (1:200; cat. no. 9198; Cell Signaling Technology, 
Inc.). Then, cells were incubated with the secondary anti-
bodies, Alexa Fluor 488 goat anti-mouse IgG (cat. no. A11001; 
Invitrogen; Thermo Fisher Scientific, Inc.) and Alexa Fluor 
488 goat anti-rabbit IgG (cat. no. A11008; Invitrogen; Thermo 
Fisher Scientific, Inc.) with 4,6-diamidino-2-phenylindole 
(Sigma-Aldrich; Merck KGaA) for 1 h at room temperature. 
Immunofluorescence staining was imaged using a ZEISS 
LSM700 confocal microscope (magnification, x40).
Statistical analysis. Data are presented as the mean ± stan-
dard deviation of three independent experiments. Student's 
t-test was used between two groups and one-way analysis of 
variance with Tukey's post hoc test were used for comparing 
multiple groups. P<0.05 was considered to indicate a statis-
tically significant difference. All statistical analyses were 
conducted using GraphPad Prism 5.01 (GraphPad Software, 
Inc., La Jolla, CA, USA).
Results
UVB and α‑MSH decrease the phosphorylation of Src 
protein in G361 cells. UVB radiation is a physical stimulus 
that increases the amount of melanin produced in human 
melanoma cells. α-MSH is also known to increase melanin 
production in human melanoma cells (18). The present study 
treated G361 cells with 5 mJ of UVB and 1 µM of α-MSH, 
which are both known stimulants of melanogenesis. As a 
result, the phosphorylation of Src protein was decreased by 
melanin‑stimulation (Fig. 1A and B). It was also confirmed 
that these melanin stimulants increased melanin production 
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in a time-dependent manner (Fig. 1C and D) Therefore, it was 
hypothesized that Src inhibition may be required for melano-
genesis in G361 cells. The present study also used 1 µM of the 
Src inhibitors SU6656 and PP2 to inhibit the phosphorylation 
of Src protein (Fig. 1E and F).
SU6656 and PP2 induce melanogenesis in G361 cells. Up to 
1,000 nM of SU6656 and PP2 were used to treat G361 cells 
as these inhibitors are toxic at high concentrations. Following 
SU6656 treatment, the pellet color of G361 cells became 
darker in a concentration-dependent manner (Fig. 2A). In 
Figure 1. Inhibition of Src phosphorylation by UVB or α-MSH. The stimulators of melanogenesis, (A) UVB and (B) α-MSH, inhibited the phosphorylation of 
Src in G361 cells. (C) UVB and (D) α-MSH promoted melanin synthesis. In addition, the Src inhibitors, (E) SU6656 and (F) PP2 reduced the levels of p-Src 
protein. Data are presented as the mean ± standard deviation (n=3). *P<0.05, **P<0.01 and ***P<0.001, as indicated. p-Src, phosphorylated Src; t-Src; total Src; 
UVB, ultraviolet B; α-MSH, α-melanocyte-stimulating hormone.
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addition, PP2 also increased the melanin content in G361 cells 
in a dose-dependent manner (Fig. 2B).
SU6656 and PP2 regulate the mRNA expression levels of 
melanogenesis‑associated genes. As MITF, TRP1, TRP2 and 
tyrosinase are key factors in mediating melanogenesis, the 
present study investigated whether Src inhibitors upregulated 
the mRNA expression of these genes. As expected, treatment 
with 100 and 1,000 nM of SU6656 for 9 days upregulated the 
mRNA expression of melanogenesis-associated genes in G361 
cells. In particular, the expression of MITF and TRP1 were 
upregulated by up to 55 and 87%, respectively (Fig. 3A). In 
addition, PP2 upregulated the mRNA expression of MITF, 
TRP1, TRP2 and tyrosinase at 1,000 nM (Fig. 3B).
Figure 2. Src inhibitors induce melanogenesis in a dose-dependent manner. (A) SU6656 and (B) PP2 increases pellet pigmentation and melanin content in a 
dose-dependent manner. Data are presented as the mean ± standard deviation (n=3). *P<0.05 and **P<0.01, as indicated.
Figure 3. Upregulation of melanogenesis-associated genes by Src inhibitors. Relative mRNA expression levels of the melanogenesis-associated genes MITF, 
TRP1, TRP2 and tyrosinase were examined by (A) SU6656 or (B) PP2 in G361 cells, and mRNA expression was induced by Src inhibitors. Data are presented 
as the mean ± standard deviation (n=3). *P<0.05, **P<0.01 and ***P<0.001, as indicated. MITF, microphthalmia-associated transcription factor; TRP, tyrosi-
nase-related protein.
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Src inhibition by siRNA upregulates the expression of mela‑
nogenesis‑associated genes. To further determine whether 
melanogenesis is specifically due to Src inhibition in G361 
cells, the present study examined the pellet color, melanin 
contents and expression of melanogenesis-association genes 
following the inhibition of Src using Src siRNA. G361 cells 
were harvested 6 days post-transfection with 20 nM of Src 
siRNA. Src inhibition using Src siRNA produced a darker 
pellet color than the negative control (Fig. 4A) and the Src 
mRNA level was downregulated effectively with ~60% 
efficiency (Fig. 4B and C). The mRNA expression levels of 
the melanogenesis-associated genes MITF, TRP1, TRP2 and 
tyrosinase were examined by RT-qPCR and sqPCR. The 
mRNA expression of MITF and TRP1 in Src knockdown cells 
was significantly upregulated by 2‑ and 2.8‑fold, respectively. 
In addition, the expression of TRP2 in Src knockdown cells 
was upregulated when compared with that of the control 
(Fig. 4B and C). However, the mRNA expression level of 
tyrosinase was not altered by Src siRNA.
SU6656 and PP2 induce p38 and CREB activation in G361 
cells. The phosphorylation of p38 and CREB reportedly serves 
a key role in melanogenesis (19). Therefore, the present study 
investigated whether Src inhibitors affect the phosphorylation 
of p38 and CREB by time course via western blot analysis. 
When G361 cells were treated with 1 µM of SU6656, the 
phosphorylation of p38 and CREB was increased over time 
as determined by western blot analysis (Fig. 5A). Similarly, 
1 µM of PP2 increased the phosphorylation of p38 and CREB 
over time as determined by western blot analysis (Fig. 5B). 
Src inhibition by SU6656 or PP2 also increased the protein 
levels of phosphorylated p38 and CREB, as presented by 
immunofluorescence staining (Fig. 5C).
Inhibition of p38 and CREB abolishes the increase in 
melanogenesis induced by SU6656 and PP2. As Src inhibitors 
activate the p38 MAPK signaling pathways and the phosphor-
ylation of CREB (19), the present study investigated whether 
inhibition of these signaling pathways attenuated the increased 
melanogenesis induced by SU6656 and PP2. As expected, the 
p38 inhibitor, SB203580 (20 µM), significantly attenuated the 
increased melanogenesis induced by the Src inhibitors SU6656 
and PP2. At the same time, it was confirmed that the activation 
of p38 was also markedly reduced (Fig. 6A and B). Similarly, 
Figure 4. Src inhibition by Src siRNA induces melanogenesis and upregulates melanogenesis-associated genes. (A) Increase in pigmentation by 20 nM Src 
siRNA treatment. (B and C) Upregulated mRNA expression levels of melanogenesis-associated genes induced by 20 nM Src siRNA; as determined by 
(B) semi-quantitative PCR and (C) reverse transcription-quantitative PCR. Data are presented as the mean ± standard deviation (n=3). #P<0.05, ##P<0.01 and 
###P<0.001, as indicated. NC, negative control; N.S, not significant; siRNA, small interfering RNA; MITF, microphthalmia‑associated transcription factor; 
TRP, tyrosinase-related protein; PCR, polymerase chain reaction.
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Figure 5. Src inhibition activates the p38 or CREB pathways. (A) Increased phosphorylation of p38 or CREB by the Src inhibitor SU6656 (1 µM) was deter-
mined by western blotting. (B) Increased phosphorylation of p38 or CREB by the Src inhibitor PP2 (1 µM) was revealed by western blotting. (C) Increased 
expression of p‑p38 or p‑CREB by SU6656 (1 µM) or PP2 (1 µM) was determined by immunofluorescence. Scale bars, 20 µm. Data are presented as the 
mean ± standard deviation (n=3). *P<0.05, **P<0.01 and ***P<0.001, as indicated. p-Src, phosphorylated Src; t-Src, total Src; CREB, cyclic adenosine mono-
phosphate response element binding.
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H‑89 (1 µM), a PKA pathway inhibitor, significantly attenu-
ated the increased melanogenesis induced by SU6656 and 
PP2. In addition, activation of CREB, which was increased by 
Src inhibitors, was also markedly decreased (Fig. 7A and B).
Discussion
c-Kit is known to be expressed in melanocytes and is associ-
ated with melanocyte proliferation, melanocyte migration and 
melanogenesis in response to SCF (20,21). c-kit is an RTK, 
as well as an epidermal growth factor receptor, a fibroblast 
growth factor receptor and a vascular endothelial growth factor 
receptor. It not only serves a role in cell survival, proliferation 
and differentiation but also is closely associated with several 
types of cancer, such as gastrointestinal stromal tumors, testic-
ular seminoma, melanoma and acute myeloid leukemia (20,22). 
Therefore, RTK inhibitors, also known as c-Kit inhibitors, 
including imatinib, sorafenib, sunitinib and dasatinib, are 
now being used as anticancer drugs, even though they are not 
specific for c‑Kit only (20,22,23). According to reports on the 
side effects of RTK inhibitors with regard to pigmentation, 
there have been conflicting reports of the pigmentary changes 
with unknown pathogenesis. Some cases have suggested that 
hypopigmentation occurs as an adverse effect of patients 
taking c-Kit inhibitors including imatinib (23-26). By contrast, 
there have also been reports that have described hyperpigmen-
tation caused by chemotherapy with c-Kit inhibitors (27-29). 
Therefore, to determine the effect of c-Kit inhibitors on 
melanogenesis in G361 cells, c-Kit inhibitors such as dasatinib 
and nilotinib (both at 0.1 M) were evaluated in the present 
study. The results revealed that dasatinib and nilotinib (both 
at 0.1 M) increased melanin production (data not shown). In 
addition, dasatinib upregulated the mRNA expression levels 
of melanogenesis-associated molecules such as MITF, TRP1, 
TRP2 and tyrosinase in G361 cells (data not shown). However, 
dasatinib is not as potent as the Src inhibitors SU6656 and 
PP2 in melanogenesis. Dasatinib inhibited c-Kit, Src and Abl. 
Therefore, the present study further examined the effect of 
Src inhibitors on melanogenesis instead of the effect of c-Kit 
inhibitors.
First, the results demonstrated that the stimulators of 
melanogenesis, UVB and α-MSH, inhibited the phosphoryla-
tion of Src in G361 cells. This result suggests that UV- and 
α-MSH-induced pigmentation could be mediated via c-Src 
inhibition. Src inhibition by the chemical inhibitors SU6656 
and PP2 induced melanogenesis in G361 cells and upregulated 
the mRNA expression levels of the melanogenesis-associated 
molecules MITF, TRP1, TRP2 and tyrosinase. Src inhibition by 
siRNA knockdown in G361 cells also induced melanogenesis 
and upregulated the mRNA expression levels of melanogen-
esis-associated genes. The p38 MAPK and PKA signaling 
pathways, which serve a key role in melanogenesis, were 
examined for Src-mediated pigmentary regulation. Src inhibi-
tion by SU6656 or PP2 induced the phosphorylation of p38 
and CREB, as determined by western blotting, and increased 
the expression levels of p-p38 and p-CREB, as revealed by 
immunofluorescence. In addition, the pigmentation and 
melanin contents of G361 cells when treated with Src inhibitors 
Figure 6. Induced melanogenesis by Src inhibitors is inhibited by the p38 inhibitor. The pigmentation and melanin contents of G361 cells induced by 
(A) SU6656 (1 µM) or (B) PP2 (1 µM) were inhibited by the p38 inhibitor SB203580 (20 µM). p-Src; phosphorylated Src, t-Src; total Src. Data are presented 
as the mean ± standard deviation (n=3). **P<0.01 and ***P<0.001, as indicated. p-Src, phosphorylated Src; t-Src, total Src.
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were significantly inhibited by the p38 and CREB inhibitors. 
Collectively, these results indicate that Src inhibition induced 
melanogenesis via the p38 MAPK and PKA signaling path-
ways in G361 cells. These data are also supported by a previous 
study that indicated that Src inhibition increased p-p38 expres-
sion levels (30). Additionally, the suppression of c-Src activity 
by PP1 and SU6656 stimulated muscle differentiation via p38 
MAPK activation (31). Dasatinib, a c-Kit inhibitor, also exerted 
an antileukemic effect via the activation of the p38 MAPK 
signaling pathways (32). Although there is little to no evidence 
on whether Src inhibitors affect CREB phosphorylation, it is 
reasonable to assume that p38 activation can activate the phos-
phorylation of CREB, which is known to be a downstream 
signal of p38 during UV-induced melanogenesis.
The activation of c-Src increases the proliferation, survival 
and invasion of cancer cells, and Src phosphorylation/activa-
tion is involved in 50% of colon, liver, breast and pancreatic 
tumors (33). Therefore, a number of tyrosine kinase inhibitors 
against c-Src, including dasatinib, have been developed for 
cancer therapy (34). c-Src is a non-receptor tyrosine kinase, 
but c-Src can be activated by many transmembrane proteins 
including adhesion receptors, RTKs, G-protein coupled 
receptors and cytokine receptors (13). Melanocytes possess a 
variety of receptors, such as melanocortin 1 receptor (MC1R; 
a type of G-protein coupled receptor) and c-Kit (a type of 
RTK), and melanin production in melanocytes is regulated 
through external stimulation to the receptors (35). Therefore, 
the MC1R and c-Kit signaling pathways in melanocytes may 
be closely associated with c-Src signaling. Understanding the 
role of the c-Src pathway in melanocytes is critical for under-
standing melanocyte physiology, and melanoma development 
and progression. The results of the present study will also 
help predict pigmentation side effects when Src inhibitors 
are used for anticancer therapy and develop novel promising 
hypopigmentation agents for hyperpigmentary disorders, such 
as melasma and aging spots. In conclusion, Src inhibition in 
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Figure 7. Induced melanogenesis by Src inhibitors is inhibited by the PKA inhibitor. Induced pigmentation and melanin contents by (A) SU6656 (1 µM) or 
(B) PP2 (1 µM) were inhibited by PKA inhibitor (H-89, 1 µM). Data are presented as the mean ± standard deviation (n=3). *P<0.05, **P<0.01 and ***P<0.001, 
as indicated. p-Src, phosphorylated Src; t-Src, total Src; PKA, protein kinase A.
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